Search
Dexamethasone Treatment Options
A collection of 1461 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
541 - 552 of 1461
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Expanded Access Treatment Protocol CA204-143
No Longer Available
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: John Muir Medical Center, Concord, California +26 locations
Conditions: Multiple Myeloma
Dexamethasone Solution and Dexamethasone in Mucolox™
Completed
Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily. Using Mucolox™ as a vehicle to deliver topical dexamethasone to the oral mucosa has the potential to effectively prolong contact time between the medication. The primary objective of this study is to determine the clinical efficacy and tolerability of compound dexamethasone at 0.5 mg/5 mL in Mucolox™ for the tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Sol Silverman Oral Medicine Clinic - UCSF, San Francisco, California
Conditions: Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Active Not Recruiting
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Stanford Medicine Ophthalmology, Palo Alto, California
Conditions: Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Completed
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +3 locations
Conditions: Multiple Myeloma
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
Active Not Recruiting
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from refractory diabetic macular edema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Stanford Medicine Ophthalmology, Palo Alto, California
Conditions: Refractory Diabetic Macular Edema
Effect of Intraoperative Dexamethasone on Post-op Dry Eye
Completed
To compare the signs and symptoms of dry eye after cataract surgery between subjects randomized to receive intraoperative dexamethasone in addition to the use of a standard topical post-op treatment regimen.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
11/20/2023
Locations: Hauser Ross Surgical Center, Sycamore, Illinois
Conditions: Dry Eye Syndromes
Dexamethasone Versus Depo Medrol in Lumbar Epidurals
Terminated
Comparison of Dexamethasone versus Depo Medrol when used in lumbar epidural injections will be conducted on subjects that have not had previous injections or have not had an injection in the last 12 months. Subjects must be receiving one level injection and not had prior surgery at that level.
Gender:
ALL
Ages:
Between 21 years and 89 years
Trial Updated:
11/20/2023
Locations: Upstate Orthpedics, East Syracuse, New York
Conditions: Lumbar Spine Disc Herniation, Lumbar Radiculitis, Lumbar Back Pain
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Recruiting
This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Chemotherapy drugs, such as bortezomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +1 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Completed
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Rocky Mountain Cancer Centers, Denver, Colorado +7 locations
Conditions: Hematologic Malignancy
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Recruiting
Stomach cancer is the fifth most common digestive cancer and third main cause of death from cancer in the world. Modern management of Gastric cancer involves a multi-disciplinary approach involving surgical oncologists, medical oncologists, gastroenterologists and oncological radiologists. The most common clinical approach to Gastric adenocarcinoma is to begin with staging, which usually involves CT scan/ MRI combined with endoscopic US for more accurate T, N staging. Once the patient is deemed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Mount Sinai West, New York, New York +2 locations
Conditions: Gastric Cancer, Stomach Cancer
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Active Not Recruiting
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +335 locations
Conditions: Multiple Myeloma in Relapse
Low Dose Aprepitant for Patients Receiving Carboplatin
Terminated
This study evaluates a simple one day prophylaxis of nausea and vomiting for patients who are getting carboplatin based chemotherapy. In addition to standard oral Dexamethasone and oral Ondansetron, participants will be given a third neurokinin 1 (NK1) antagonist agent, either a single dose of oral Aprepitant or intravenous (IV) Fosaprepitant (they have been shown to be equally effective) to improve prevention of nausea and vomiting. No medications need to be taken beyond day 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Jacobi Medical Center, Bronx, New York +1 locations
Conditions: Chemotherapy-induced Nausea and Vomiting
541 - 552 of 1461